Cequent Pharmaceuticals announced that Harvard Medical School’s Judy Lieberman has joined its scientific advisory board.
Lieberman, well-known for her work in RNAi delivery, is a senior investigator at Harvard’s Immune Disease Institute.She holds a PhD in theoretical physics from Rockefeller Universityand an MD through the Harvard-Massachusetts Institute of Technology program in health, science, and technology.